PMID- 32133044
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200308
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 11
IP  - 7
DP  - 2020 Feb 18
TI  - Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, 
      compared with etoposide phosphate, in dogs with naturally occurring lymphoma.
PG  - 671-686
LID - 10.18632/oncotarget.27461 [doi]
AB  - Purpose: F14512 is an epipodophyllotoxin derivative from etoposide, combined with 
      a spermine moiety introduced as a cell delivery vector. The objective of this 
      study was to compare the safety and antitumor activity of F14512 and etoposide 
      phosphate in dogs with spontaneous non-Hodgkin lymphoma (NHL) and to investigate 
      the potential benefit of F14512 in P-glycoprotein (Pgp) overexpressing lymphomas. 
      Experimental Design: Forty-eight client-owned dogs with intermediate to 
      high-grade NHL were enrolled into a randomized, double-blind trial of F14512 
      versus etoposide phosphate. Endpoints included safety and therapeutic efficacy. 
      Results: Twenty-five dogs were randomized to receive F14512 and 23 dogs to 
      receive etoposide phosphate. All adverse events (AEs) were reversible, and no 
      treatment-related death was reported. Hematologic AEs were more severe with 
      F14512 and gastrointestinal AEs were more frequent with etoposide phosphate. 
      F14512 exhibited similar response rate and progression-free survival (PFS) as 
      etoposide phosphate in the global treated population. Subgroup analysis of dogs 
      with Pgp-overexpressing NHL showed a significant improvement in PFS in dogs 
      treated with F14512 compared with etoposide phosphate. Conclusion: F14512 showed 
      strong therapeutic efficacy against spontaneous NHL and exhibited a clinical 
      benefice in Pgp-overexpressing lymphoma superior to etoposide phosphate. The 
      results clearly justify the evaluation of F14512 in human clinical trials.
CI  - Copyright: (c) 2020 Boye et al.
FAU - Boye, Pierre
AU  - Boye P
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
AD  - Oncovet, Villeneuve d'Ascq, France.
AD  - Current address: Department of Small Animal Teaching Hospital, The Royal (Dick) 
      School of Veterinary Studies and The Roslin Institute, University of Edinburgh, 
      UK.
FAU - Floch, Franck
AU  - Floch F
AD  - Oncovet, Villeneuve d'Ascq, France.
FAU - Serres, Francois
AU  - Serres F
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
AD  - Oncovet, Villeneuve d'Ascq, France.
FAU - Segaoula, Zacharie
AU  - Segaoula Z
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
AD  - Universite de Lille, JPARC - Centre de Recherche Jean-Pierre Aubert, 
      Neurosciences et Cancer, Lille, France.
FAU - Hordeaux, Juliette
AU  - Hordeaux J
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Pascal, Quentin
AU  - Pascal Q
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Coste, Virginie
AU  - Coste V
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Courapied, Sandy
AU  - Courapied S
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Bouchaert, Emmanuel
AU  - Bouchaert E
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Rybicka, Agata
AU  - Rybicka A
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Mazuy, Claire
AU  - Mazuy C
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
FAU - Marescaux, Laurent
AU  - Marescaux L
AD  - Oncovet, Villeneuve d'Ascq, France.
FAU - Geeraert, Kevyn
AU  - Geeraert K
AD  - Oncovet, Villeneuve d'Ascq, France.
FAU - Fournel-Fleury, Corinne
AU  - Fournel-Fleury C
AD  - Laboratoire Fleury-Fournel ALVEDIA, Limonest, France.
FAU - Duhamel, Alain
AU  - Duhamel A
AD  - Universite Lille, Sante Publique: Epidemiologie et Qualite des Soins, Lille, 
      France.
FAU - Machuron, Francois
AU  - Machuron F
AD  - Universite Lille, Sante Publique: Epidemiologie et Qualite des Soins, Lille, 
      France.
FAU - Ferre, Pierre
AU  - Ferre P
AD  - Institut de Recherche Pierre Fabre, Toulouse, France.
FAU - Petain, Aurelie
AU  - Petain A
AD  - Institut de Recherche Pierre Fabre, Toulouse, France.
FAU - Guilbaud, Nicolas
AU  - Guilbaud N
AD  - Institut de Recherche Pierre Fabre, Toulouse, France.
FAU - Tierny, Dominique
AU  - Tierny D
AD  - OCR (Oncovet-Clinical-Research), Loos, France.
AD  - Oncovet, Villeneuve d'Ascq, France.
FAU - Gomes, Bruno
AU  - Gomes B
AD  - Institut de Recherche Pierre Fabre, Toulouse, France.
AD  - Current address: Hoffmann-La Roche, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200218
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC7041934
OTO - NOTNLM
OT  - F14512
OT  - P-glycoprotein
OT  - etoposide phosphate
OT  - non-Hodgkin lymphoma
OT  - pet dog model
COIS- CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
EDAT- 2020/03/07 06:00
MHDA- 2020/03/07 06:01
PMCR- 2020/02/18
CRDT- 2020/03/06 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/03/06 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/03/07 06:01 [medline]
PHST- 2020/02/18 00:00 [pmc-release]
AID - 27461 [pii]
AID - 10.18632/oncotarget.27461 [doi]
PST - epublish
SO  - Oncotarget. 2020 Feb 18;11(7):671-686. doi: 10.18632/oncotarget.27461. 
      eCollection 2020 Feb 18.